Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis (Q24243033)

metabolic dysfunction–associated steatotic liver disease

Europe PubMed Central

title

Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis (English)

0 references

0 references

0 references

0 references

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

Flavio Lirussi

1

0 references

Ezio Mastropasqua

series ordinal

2

0 references

Serena Orando

series ordinal

3

0 references

Rocco Orlando

series ordinal

4

0 references

publication date

24 January 2007

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Searching for coeliac disease in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Unsuspected cirrhosis discovered during elective obesity operations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Nonalcoholic steatohepatitis: definition and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Etiopathogenesis of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Non-alcoholic fatty liver disease: current concepts and management strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Helicobacter pylori infection increases mucosal permeability of the stomach and intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Probiotics in inflammatory bowel disease: is it all gut flora modulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Is coeliac disease a confounding factor in the diagnosis of NASH?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0-6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

The role of probiotics in the treatment and prevention of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Molecular analysis of commensal host-microbial relationships in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Animal models of steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Quantitative approach in the study of adhesion of lactic acid bacteria to intestinal cells and their competition with enterobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

A comparison of methods to detect publication bias in meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Probiotic bacteria enhance murine and human intestinal epithelial barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Update on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Functional food science and gastrointestinal physiology and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Non-alcoholic fatty liver disease: lumen–liver interactions and possible role for probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Increased orocecal transit time in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Nonalcoholic fatty liver disease: an agenda for clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

7 January 2021

Probiotics--role in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

7 January 2021

Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

7 January 2021

Probiotic therapy fails to improve gut permeability in a hapten model of colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

7 January 2021

Gut-liver axis: a new point of attack to treat chronic liver damage?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

7 January 2021

Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005165.PUB2

7 January 2021

10.1002/14651858.CD005165.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

856540

856540

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference